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Abstract 
Vitamin D has antiproliferative, antiangiogenic, and apoptotic properties.  There is some 
evidence supporting an association between vitamin D-related gene variants and prostate cancer 
risk.  We report results from this population-based case-control study of genes encoding for the 
vitamin D receptor (VDR), the vitamin D activating enzyme 1-α-hydroxylase (CYP27B1) and 
deactivating enzyme 24-hydroxylase (CYP24A1).  Forty-eight tagging single nucleotide 
polymorphisms (tagSNPs) were analyzed in 827 incident prostate cancer cases diagnosed in 
2002 through 2005 and 787 age-matched controls. Contrary to some earlier studies, we found no 
strong evidence of altered risk of developing prostate cancer overall or within clinical measures 
of tumor aggressiveness for any of the tagSNPs when they were assessed individually or in 
haplotypes.  
 
 3
Introduction 
Vitamin D has been shown to reduce cellular proliferation, increase apoptosis, and inhibit 
angiogenesis 1;2.  The link to prostate cancer (PCa) is supported by ecological studies 
demonstrating an inverse relationship between PCa incidence and ultraviolet (UV) exposure, 
which is the primary source of vitamin D3.  Serum studies, which have provided inconsistent 
results for a relationship between vitamin D status and PCa risk, may not capture the relevant 
exposure period since not only does prostate carcinogenesis most likely begin decades prior to 
measurement, but 1-α-hydroxylase, the enzyme that activates vitamin D, is down-regulated early 
in the neoplastic process of PCa cells 4-6.     
This study performed a comprehensive analysis of three genes in the vitamin D 
metabolism pathway: CYP27B1, encoding for 1-α-hydroxylase, which converts into the active 
form of the hormone 1,25-dihydroxy-vitamin D [1,25(OH)2D]; VDR, encoding for the nuclear 
vitamin D receptor, which mediates all functions of 1,25(OH)2D; and, CYP24A1, encoding for 
24-hydroxylase, which catabolizes 1,25(OH)2D into its excretion product.  This population-based 
case-control study was completed to follow-up on our prior study which reported for two VDR 
loci, rs2107301 and rs2238135, carriers of the less common allele had higher risks of PCa [OR 
2.47 (95% CI 1.52-4.00) and OR 1.95 (95% CI 1.17-3.26), respectively]  and reported no 
association with PCa risk for the most frequently studied VDR polymorphisms FokI 
(rs10735810), BsmI (rs1544410), ApaI (rs7975232), and TaqI (rs731236)7.  
 
Materials and Methods 
Study Population  
Study subjects were enrolled in a population-based prostate cancer case-control study that 
has been described previously8. Eligible individuals were Caucasian or African American men. 
Cases were diagnosed with histologically confirmed prostate cancer between ages 35-74 years 
from January 1, 2002 to December 31, 2005.  Prostate cancer cases were identified from the 
metropolitan Seattle-Puget Sound population-based tumor registry that is operated as part of 
National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program.  Of 
the 1,001 eligible interviewed cases, 827 (82.6%) had peripheral blood leukocyte samples 
collected. Eligible controls were recruited evenly throughout the ascertainment period for cases 
using random digit telephone dialing (RDD) and frequency matched to cases by 5-year age 
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groups.  Of the 942 eligible interviewed controls, 787 (83.5%) had peripheral blood leukocyte 
samples collected.  This study was approved by Fred Hutchinson Cancer Research Center’s 
Institutional Review Board and genotyping was approved by the Internal Review Board of the 
National Human Genome Research Institute.   
 
SNP Selection and Genotyping 
SNPs capturing genetic variability in the VDR9 and CYP27B110 genes were selected using 
resequencing data, while SNP selection for CYP24A111 used publicly available data from the 
HapMap consortium1.  SNP selection and genotyping duplicated methods described in the 
previous case-control study7. Percent agreement of blind duplicates was ≥98% for all tagSNPs.   
 
Statistical Analysis 
Statistical methods were identical to our previous study7.  All SNPs, except for rs912505 
in CYP24A1, were consistent (P > 0.05) with HWE among Caucasian controls.  Data were 
analyzed using unconditional logistic regression to calculate odds ratios as estimates of relative 
risk of prostate cancer associated with SNP genotypes. We included age and stratified by race in 
all regression models. We assessed possible confounding effects of variables listed in Table 1 
and found none appreciably altered risk estimates, thus did not include them as covariates.  
Global tests of association, which were estimated by comparing an adjusted model that included 
all SNPs for a given gene to the null model that only included adjustment covariates, 
automatically adjusted for multiple testing based on degrees of freedom of the corresponding χ2 
test12.  Multiple comparisons were also accounted for by using permutations to calculate exact p-
values for each significant individual SNP (α = 0.05).  All analyses were done using STATA 
statistical package (version 9.2, STATA Corp., College Station, TX).   
 
Results 
Cases and controls were similar in age (mean in cases, 61.7 years; in controls, 61.1 
years).  Cases had a higher percentage of African Americans, subjects reporting a family history 
of prostate cancer, and subjects with a history of PSA testing (Table 1). The majority of prostate 
cancers were local stage tumors with low/moderate Gleason scores.  
                                                 
1 www.hapmap.org 
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There was no strong evidence of altered risk of developing prostate cancer for any 
tagSNPs evaluated (Table 2) or haplotypes (data not shown). In Caucasians two loci (VDR: 
rs4760674 and CYP27B1: rs4809960) showed slightly lower relative risks of prostate cancer for 
homozygous variant versus homozygous wildtype carriers [OR 0.68 (95% CI 0.48-0.95) and OR 
0.77 (95% CI 0.62-0.96), respectively], but after adjusting for multiple comparisons these 
associations were no longer significant.  Stratification by measures of tumor aggressiveness, such 
as Gleason score or stage, did not reveal significant associations of risk with genotypes. Lastly, 
there was no evidence of effect modification by total vitamin D or calcium intake. 
 
Discussion 
One goal of this study was to evaluate earlier findings by our group that showed VDR 
tagSNPs rs2107301 and rs2238135 to be significantly associated with prostate cancer7. We did 
not replicate our earlier findings or identify any additional genotypes associated with PCa risk in 
this comprehensive group of tagSNPs for VDR, CYP27B1, and CYP24A1 genes. Our findings 
corroborate a lack of an association between PCa risk and frequently studied VDR 
polymorphisms BsmI (rs1544410), TaqI (rs731236), ApaI (rs7975232), and FokI 
(rs10735810)7;13;14. 
This study attempted to capture genetic variation within a pathway of genes. Assuming 
80% power, the minimal detectable odds ratio was 0.46 or 1.76 for evaluating tagSNPs with a 
minor allele frequency of 5% or greater. We were underpowered to examine risk within African 
Americans, moreover, since polymorphic alleles in VDR, CYP27A1 and CYP24B1 differ by 
ethnicity and tagSNP selection was based on a Caucasian population, gene coverage for an 
African American population is not complete.  We did not find any evidence that vitamin D 
intake was an effect modifier; however, we were unable to account for plasma vitamin D levels 
or UV light exposure. 
Our findings suggest that common genotypic variation found in VDR, CYP27A1 and 
CYP24B1 has little or no effect on overall prostate cancer risk. Future studies may reveal that 
these genotypes effect disease progression rather than risk of developing disease. 
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Table 1. Distribution and risk estimates for selected characteristics of cases and controls, King County, 
Washington, 2002-2005 
  Cases (%) Controls (%) Adjusted OR* 
    (n=827) (n=787) (95% CI) 
Age group    
 35-49 78 (9.4) 76 (9.7)  
 50-54 85 (10.3) 95 (12.1)  
 55-59 147 (17.8) 149 (18.9)  
 60-64 182 (22) 157 (19.9)  
 65-69 177 (21.4) 164 (20.8)  
 70-74 158 (19.1) 146 (18.6)  
Race    
 Caucasian 711 (86) 718 (91.2) 1.00 (reference) 
 African American 116 (14) 69 (8.8) 1.79 (1.30-2.47) 
First-degree relative with prostate cancer   
 No 635 (76.8) 694 (88.2) 1.00 (reference) 
 Yes 192 (23.2) 93 (11.8) 2.27 (1.73-2.98) 
Number of PSA tests†    
 None 182 (22) 193 (24.5) 1.00 (reference) 
  1-2 138 (16.7) 144 (18.3) 1.04 (0.76-1.43) 
  3-4 143 (17.3) 112 (14.2) 1.43 (1.03-1.99) 
 ≥5 312 (37.7) 207 (26.3) 1.70 (1.28-2.26) 
 Unknown 52 (6.3) 131 (16.6)  
Total vitamin D (ug/d) ‡    
 ≤ 6.9 188 (22.7) 190 (24.1) 1.00 (reference) 
 7.0-12.9 220 (26.6) 189 (24) 1.18 (0.89-1.57) 
 13.0-17.4 211 (25.5) 189 (24) 1.12 (0.85-1.49) 
 ≥ 17.5 180 (21.8) 190 (24.1) 0.95 (0.72-1.27) 
 Unknown 28 (3.4) 29 (3.7)  
Stage of PCa at diagnosis    
 Local 676 (81.7)   
 Regional 134 (16.2)   
 Distant 17 (2.1)   
Gleason score at diagnosis    
 2-6, 7 (3+4) 674 (81.5)   
 7( 4+3), 8-10 148 (17.9)   
  Unknown 5 (0.6)    
* Adjusted for age. 
† PSA tests done in the previous 5 years before reference date. 
‡ Total daily intake from diet and supplements. 
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Table 2. Genotype distribution and odds ratios (95% CI) for associations between VDR (vitamin D receptor), CYP27B1 (1-alpha-
hydroxlase) and CYP24A1 (24-hydroxylase) genotypes and prostate cancer risk by race. 
   Caucasians     African Americans    
   Cases (%) Controls (%) Adjusted OR†  Cases (%) Controls (%) Adjusted OR†  
Gene SNP Genotype (n=711)* (n=718)* (95% CI) Ptrend† (n=116)* (n=69)* (95% CI) Ptrend† 
VDR rs2544038 TT 218(31) 223(31) 1.00 (reference)  50(43) 24(36) 1.00 (reference)  
 Block A CT 347(49) 363(51) 0.98 (0.77-1.24)   53(46) 33(49) 0.78 (0.39-1.59)   
 (23295bp 3' of STP) CC 140(20) 130(18) 1.10 (0.81-1.49)   12(10) 10(15) 0.57 (0.20-1.62)   
  CC+CT   1.01 (0.81-1.26) 0.61   0.73 (0.37-1.44) 0.28 
 rs739837 TT 193(27) 202(28) 1.00 (reference)  43(37) 24(36) 1.00 (reference)  
 Block B GT 367(52) 342(48) 1.12 (0.88-1.44)   55(48) 31(46) 1.26 (0.61-2.62)   
 (Ex11+568) GG 143(20) 169(24) 0.88 (0.66-1.19)   17(15) 12(18) 1.09 (0.41-2.91)   
  GG+GT   1.04 (0.83-1.32) 0.50   1.22 (0.61-2.42) 0.74 
 rs731236 TT 242(35) 261(37) 1.00 (reference)  58(51) 29(46) 1.00 (reference)  
 Block B CT 349(50) 328(47) 1.15 (0.91-1.45)   45(39) 27(43) 0.71 (0.35-1.45)   
 (Ex11+32) CC 106(15) 108(15) 1.06 (0.77-1.46)   11(10) 7(11) 0.64 (0.21-1.97)   
  CC+CT   1.13 (0.91-1.40) 0.50   0.70 (0.36-1.36) 0.30 
 rs1544410 AA 239 (34.9) 255 (36.4) 1.00 (reference)  57 (51.4) 27 (40.9) 1.00 (reference)  
 Block B AG 339 (49.6) 331 (47.2) 0.45 (0.87-1.38)   47 (42.3) 26 (39.4) 0.95 (0.50-2.10)   
 (IVS10+283) GG 106(15.5) 115 (16.4) 0.92 (0.72-1.35)   7 (6.3) 13 (19.7) 0.02 (0.09-0.80)  
  GG+AG   0.58 (0.85-1.33) 0.89   0.41 (0.39-1.47) 0.07 
 rs2239182 GG 188(27) 190(27) 1.00 (reference)  38(33) 25(37) 1.00 (reference)  
 Block B AG 347(49) 340(48) 1.03 (0.80-1.32)   60(52) 34(51) 1.16 (0.57-2.36)   
 (IVS5+3419) AA 167(24) 185(26) 0.91 (0.68-1.22)   17(15) 8(12) 1.04 (0.36-3.05)   
  AA+AG   0.99 (0.78-1.25) 0.54   1.14 (0.58-2.24) 0.82 
 rs2107301§ CC 383(55) 369(53) 1.00 (reference)  76(67) 44(70) 1.00 (reference)  
 Block B CT 265(38) 274(39) 0.93 (0.75-1.16)   34(30) 19(30)    
 (IVS5+3260) TT 50(7) 54(8) 0.89 (0.59-1.34)   4(4) 0(0)   
  TT+CT   0.92 (0.75-1.14) 0.45   0.82 (0.40-1.71)  
 rs2239181 TT 542(79) 571(81) 1.00 (reference)  89(78) 52(78) 1.00 (reference)  
 Block B GT 142(21) 126(18) 1.19 (0.91-1.55)   23(20) 15(22)    
 (IVS5+2881) GG 5(1) 11(2) 0.48 (0.17-1.39)   2(2) 0(0)   
  GG+GT   1.13 (0.87-1.47) 0.62   0.57 (0.25-1.29)  
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 rs2238139 TT 404(57) 434(61) 1.00 (reference)  70(61) 38(57) 1.00 (reference)  
 Block B CT 270(38) 247(35) 1.17 (0.94-1.46)   41(36) 28(42) 1.04 (0.52-2.06)   
 (IVS5+2550) CC 30(4) 34(5) 0.94 (0.57-1.57)   4(3) 1(1) 4.72 (0.45-49.66)   
  CC+CT   1.15 (0.93-1.42) 0.36   1.13 (0.58-2.22) 0.46 
 rs3782905 CC 328(47) 344(49) 1.00 (reference)  68(61) 38(57) 1.00 (reference)  
 Block B CG 302(43) 301(42) 1.05 (0.84-1.31)   41(37) 27(40) 0.80 (0.41-1.59)   
 (IVS4+6584  ) GG 66(9) 64(9) 1.08 (0.74-1.58)   3(3) 2(3) 0.94 (0.13-6.66)   
  GG+CG   1.06 (0.86-1.30) 0.59   0.81 (0.42-1.58) 0.59 
 rs7974708 TT 303(43) 323(45) 1.00 (reference)  78(68) 43(64) 1.00 (reference)  
 Block B CT 322(46) 319(44) 1.08 (0.86-1.34)   33(29) 20(30) 1.23 (0.59-2.57)   
 ( IVS4+2586) CC 79(11) 75(10) 1.12 (0.79-1.60)   4(3) 4(6) 0.62 (0.12-3.10)   
  CC+CT   1.08 (0.88-1.34) 0.43   1.13 (0.56-2.26) 0.96 
 rs11168275 AA 415(59) 406(57) 1.00 (reference)  46(40) 27(40) 1.00 (reference)  
 Block B AG 253(36) 268(37) 0.92 (0.74-1.15)   56(49) 34(51) 0.86 (0.43-1.72)   
 (IVS4+476) GG 37(5) 42(6) 0.86 (0.54-1.37)   13(11) 6(9) 1.51 (0.47-4.83)   
  GG+AG   0.91 (0.74-1.13) 0.38   0.95 (0.49-1.84) 0.76 
 rs10735810 GG 262(37) 263(37) 1.00 (reference)  65(57) 39(58) 1.00 (reference)  
 No Block AG 335(48) 352(49) 0.96 (0.76-1.20)   48(42) 24(36) 1.07 (0.54-2.12)   
 (Ex4+4) AA 108(15) 101(14) 1.07 (0.78-1.48)   2(2) 4(6) 0.19 (0.02-1.54)   
  AA+AG   0.98 (0.79-1.22) 0.83   0.95 (0.49-1.84) 0.52 
 rs2408876 TT 254(37) 232(33) 1.00 (reference)  32(28) 17(25) 1.00 (reference)  
 Block C CT 343(49) 356(51) 0.88 (0.70-1.11)   59(52) 34(51) 1.07 (0.49-2.35)   
 (IVS3-667) CC 96(14) 116(16) 0.75 (0.55-1.04)   22(19) 16(24) 0.85 (0.34-2.17)   
  CC+CT   0.85 (0.68-1.06) 0.08   1.00 (0.48-2.10) 0.76 
 rs2238135§ GG 404(58) 405(57) 1.00 (reference)  41(36) 25(38) 1.00 (reference)  
 Block C CG 255(37) 255(36) 1.00 (0.80-1.25)   55(48) 35(53) 0.79 (0.39-1.60)   
 (IVS2-1633) CC 34(5) 48(7) 0.71 (0.45-1.12)   18(16) 6(9) 1.64 (0.54-4.99)   
  CC+CG   0.96 (0.77-1.18) 0.35   0.91 (0.46-1.80) 0.68 
 rs10875694 AA 494(71) 475(68) 1.00 (reference)  82(73) 50(75) 1.00 (reference)  
 Block C AT 183(26) 206(29) 0.85 (0.67-1.08)   29(26) 16(24) 1.00 (0.46-2.14)   
 (IVS2-5103) TT 14(2) 21(3) 0.64 (0.32-1.28)   1(1) 1(1) 0.70 (0.04-11.62)   
  TT+AT   0.83 (0.66-1.05) 0.09   0.98 (0.46-2.07) 0.91 
 9
 
 rs11168287 TT 159(23) 171(24) 1.00 (reference)  54(47) 36(54) 1.00 (reference)  
 Block C CT 359(51) 364(51) 1.06 (0.82-1.38)   53(46) 26(39) 1.64 (0.83-3.28)   
 (IVS2-8206) CC 180(26) 176(25) 1.10 (0.81-1.48)   8(7) 5(7) 1.26 (0.35-4.52)   
  CC+CT   1.07 (0.84-1.37) 0.54   1.58 (0.82-3.06) 0.28 
 rs7299460 CC 343(49) 350(49) 1.00 (reference)  9(8) 10(15) 1.00 (reference)  
 Block C CT 291(42) 309(43) 0.96 (0.77-1.20)   44(39) 26(39) 2.05 (0.68-6.23)   
 (IVS1+2470) TT 66(9) 54(8) 1.25 (0.85-1.84)   61(54) 31(46) 2.30 (0.78-6.81)   
  TT+CT   1.00 (0.81-1.24) 0.57   2.19 (0.77-6.19) 0.20 
 rs11168314 CC 418(60) 461(65) 1.00 (reference)  49(43) 34(51) 1.00 (reference)  
 Block C CT 253(36) 217(31) 1.28 (1.03-1.61)  51(45) 25(37) 1.45 (0.72-2.92)   
 (-27390) TT 23(3) 26(4) 0.98 (0.55-1.74)   13(12) 8(12) 1.62 (0.56-4.67)   
  TT+CT   1.25 (1.01-1.56) 0.10   1.49 (0.77-2.87) 0.25 
 rs4073729 CC 487(71) 512(73) 1.00 (reference)  68(61) 45(68) 1.00 (reference)  
 Block C CT 185(27) 175(25) 1.11 (0.87-1.41)   40(36) 21(32)    
 (-20950) TT 17(2) 19(3) 0.95 (0.49-1.85)   4(4) 0(0)   
  TT+CT   1.09 (0.87-1.38) 0.55   1.52 (0.76-3.05)  
 rs4760674 CC 245(37) 248(36) 1.00 (reference)  57(53) 26(40) 1.00 (reference)  
 Block C AC 346(52) 326(47) 1.07 (0.85-1.36)   47(44) 33(51) 0.59 (0.29-1.19)   
 (-1005) AA 76(11) 114(17) 0.68 (0.48-0.95)  4(4) 6(9) 0.26 (0.06-1.16)   
  AA+AC   0.97 (0.78-1.21) 0.11   0.54 (0.27-1.07) 0.04 
 rs6823 CC 217(31) 213(30) 1.00 (reference)  53(46) 25(38) 1.00 (reference)  
 Block C CG 358(52) 347(49) 1.01 (0.80-1.29)   50(44) 31(47) 0.81 (0.40-1.64)   
 (Ex7-250) GG 118(17) 147(21) 0.79 (0.58-1.07)   11(10) 10(15) 0.63 (0.22-1.78)   
  GG+CG   0.95 (0.75-1.19) 0.19   0.76 (0.39-1.49) 0.35 
 rs2071358 CC 457(66) 470(67) 1.00 (reference)  54(48) 43(64) 1.00 (reference)  
 Block C AC 212(31) 212(30) 1.03 (0.82-1.29)   51(45) 20(30) 1.81 (0.90-3.64)   
 (740bp 3' of STP) AA 24(3) 22(3) 1.12 (0.62-2.02)   8(7) 4(6) 1.46 (0.38-5.58)   
  AA+AC   1.04 (0.83-1.29) 0.70   1.75 (0.90-3.40) 0.16 
CYP27B1            
 rs3782130  AA 637(92) 636(92) 1.00 (reference)  97(85) 54(86) 1.00 (reference)  
 Block A AC 50(7) 52(8)    15(13) 8(13) 0.89 (0.33-2.40)   
  CC 2(0) 0(0)   2(2) 1(2) 1.05 (0.09-12.46)   
  CC+AC   1.00 (0.67-1.49)    0.91 (0.35-2.32) 0.82 
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 rs4646537  CC 319(45) 314(44) 1.00 (reference)  85(74) 50(75) 1.00 (reference)  
 No Block CG 324(46) 325(45) 0.98 (0.79-1.22)   28(24) 16(24) 1.16 (0.54-2.48)   
 (IVS8+113) GG 61(9) 77(11) 0.78 (0.54-1.13)   2(2) 1(1) 0.75 (0.06-9.98)   
  GG+CG   0.94 (0.76-1.16) 0.30   1.13 (0.54-2.37) 0.82 
CYP24A1            
 rs927650  CC 172(25) 181(25) 1.00 (reference)  62(54) 34(51) 1.00 (reference)  
 Block A CT 354(50) 373(52) 1.00 (0.78-1.29)   44(39) 29(43) 0.84 (0.43-1.67)   
 (IVS11+967) TT 175(25) 161(23) 1.15 (0.85-1.55)   8(7) 4(6) 1.30 (0.34-4.93)   
  TT+CT   1.04 (0.82-1.33) 0.38   0.90 (0.47-1.73) 0.97 
 rs912505  AA 468(67) 437(61) 1.00 (reference)  44(38) 26(39) 1.00 (reference)  
 Block A AG 212(30) 258(36) 0.77 (0.61-0.96)  51(44) 22(33) 1.74 (0.81-3.73)   
 (IVS7-1179) GG 23(3) 21(3) 1.02 (0.56-1.87)   20(17) 19(28) 0.85 (0.36-2.02)   
  GG+AG   0.79 (0.63-0.98) 0.07   1.33 (0.67-2.62) 0.93 
 rs6127118  GG 419(60) 425(60) 1.00 (reference)  61(53) 33(49) 1.00 (reference)  
 Block B AG 278(40) 287(40)    54(47) 34(51)    
 (IVS7+204) AA 0(0) 0(0)   0(0) 0(0)   
  AA+AG   0.98 (0.79-1.22)    1.02 (0.53-1.96)  
 rs6068816  CC 558(80) 580(81) 1.00 (reference)  103(90) 62(93) 1.00 (reference)  
 Block B CT 135(19) 127(18) 1.11 (0.84-1.45)   11(10) 3(4) 1.84 (0.44-7.63)   
 (Ex6+12) TT 6(1) 5(1) 1.25 (0.38-4.11)   1(1) 2(3) 0.21 (0.02-2.69)   
  TT+CT   1.11 (0.85-1.45) 0.42   1.13 (0.35-3.71) 0.75 
 rs2762939  GG 380(54) 376(53) 1.00 (reference)  29(25) 13(19) 1.00 (reference)  
 Block B CG 272(39) 294(41) 0.92 (0.74-1.14)   48(42) 32(48) 0.66 (0.28-1.55)   
 (IVS5-149) CC 50(7) 45(6) 1.10 (0.72-1.68)   37(32) 22(33) 0.82 (0.33-2.03)   
  CC+CG   0.94 (0.76-1.16) 0.83   0.73 (0.33-1.60) 0.75 
 rs2244719  TT 209(30) 201(28) 1.00 (reference)  62(55) 38(58) 1.00 (reference)  
 Block C CT 328(48) 371(52) 0.85 (0.67-1.09)   41(36) 25(38) 0.97 (0.49-1.95)   
 (IVS4-486) CC 153(22) 136(19) 1.08 (0.80-1.46)   10(9) 3(5) 1.68 (0.41-6.87)   
  CC+CT   0.91 (0.73-1.15) 0.78   1.06 (0.55-2.05) 0.66 
 rs3787557  TT 528(75) 518(72) 1.00 (reference)  107(93) 61(91) 1.00 (reference)  
 Block C CT 168(24) 187(26) 0.88 (0.69-1.12)   8(7) 6(9)    
 (IVS4-763 ) CC 8(1) 12(2) 0.65 (0.26-1.61)   0(0) 0(0)   
  CC+CT   0.87 (0.69-1.10) 0.19   0.68 (0.20-2.33) 0.54 
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 rs2181874  GG 406(58) 400(56) 1.00 (reference)  37(32) 22(33) 1.00 (reference)  
 No Block AG 249(35) 273(38) 0.90 (0.72-1.12)   56(49) 31(46) 1.22 (0.58-2.58)   
 (IVS4+1653) AA 48(7) 41(6) 1.15 (0.74-1.79)   22(19) 14(21) 0.83 (0.32-2.10)   
  AA+AG   0.93 (0.76-1.15) 0.85   1.09 (0.55-2.19) 0.81 
 rs4809960  TT 432(62) 387(56) 1.00 (reference)  93(83) 46(73) 1.00 (reference)  
 Block D CT 220(32) 260(38) 0.76 (0.60-0.95)  18(16) 17(27)    
 (IVS4+58) CC 45(6) 46(7) 0.87 (0.57-1.35)   1(1) 0(0)   
  CC+CT   0.78 (0.63-0.96) 0.06   0.48 (0.21-1.08)  
 rs2296241  AA 170(25) 183(26) 1.00 (reference)  37(33) 15(23) 1.00 (reference)  
 Block D AG 356(51) 371(53) 1.03 (0.80-1.33)   50(45) 39(59) 0.49 (0.23-1.08)   
 (Ex4+9) GG 166(24) 151(21) 1.18 (0.87-1.61)   25(22) 12(18) 0.69 (0.26-1.85)   
  GG+AG   1.08 (0.85-1.37) 0.28   0.54 (0.26-1.15) 0.35 
 rs2245153  TT 485(69) 451(63) 1.00 (reference)  47(41) 31(46) 1.00 (reference)  
 No Block CT 192(27) 233(33) 0.77 (0.61-0.96)  57(50) 31(46) 1.29 (0.65-2.55)   
 (IVS3-179) CC 26(4) 31(4) 0.78 (0.46-1.33)   11(10) 5(7) 1.11 (0.32-3.82)   
  CC+CT   0.77 (0.62-0.96) 0.03   1.26 (0.65-2.43) 0.60 
 rs2585428  GG 218(31) 203(29) 1.00 (reference)  33(29) 19(30) 1.00 (reference)  
 No Block AG 348(50) 353(51) 0.92 (0.72-1.17)   48(42) 29(46) 1.03 (0.47-2.27)   
 (IVS3-670) AA 132(19) 141(20) 0.87 (0.64-1.18)   33(29) 15(24) 1.26 (0.52-3.08)   
  AA+AG   0.90 (0.72-1.14) 0.36   1.12 (0.54-2.31) 0.61 
 rs13038432  AA 593(86) 593(84) 1.00 (reference)  109(96) 66(99) 1.00 (reference)  
 No Block AG 87(13) 103(15) 0.85 (0.62-1.15)   5(4) 1(1)    
 (IVS3+814) GG 12(2) 8(1) 1.50 (0.61-3.70)   0(0) 0(0)   
  GG+AG   0.89 (0.67-1.20) 0.70   1.52 (0.17-13.95) 0.71 
 rs6022999  AA 413(58) 419(58) 1.00 (reference)  23(20) 7(10) 1.00 (reference)  
 No Block AG 253(36) 266(37) 0.97 (0.78-1.20)   47(41) 32(48) 0.77 (0.27-2.16)   
 (IVS3+103) GG 41(6) 32(4) 1.30 (0.80-2.10)   45(39) 28(42) 0.82 (0.29-2.32)   
  GG+AG   1.00 (0.81-1.24) 0.67   0.79 (0.30-2.10) 0.82 
* Variable numbers of cases and controls reflect instances of failed genotyping. 
† Adjusted for age. Odd ratios with a  p ≤ 0.05 are bolded. These did not remain significant after adjustment for multiple comparisons. If there are no case or control 
homozygote carriers of less common allele, then only dominant model risk estimate is shown.  
‡ Analysis for linear trend according to the number of variant alleles. If there are no case or control homozygote carriers of less common allele this analysis is omitted.  
§ These polymorphisms were found to be significantly associated with PCa risk in the prior study done by Holick et al7. 
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